Neoadjuvant chemotherapy combined with bevacizumab for resectable colorectal liver metastasis with risk factors for recurrence: a multicenter real-world study

Background: Currently, guidelines prohibit the addition of targeted drugs in neoadjuvant chemotherapy (NAC) for initially resectable colorectal liver metastasis (CRLM). Objective: Nevertheless, efficacy data of NAC combined with bevacizumab (Bev) for initially resectable CRLM with risk factors for r...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Yizhen Chen, Yuanyuan Zheng, Jia Wu, Rong Ye, Hangdong Jia, Zhenyuan Zhou, Weijie Chen, Linwei Xu, Yuhua Zhang, Ming Zheng
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	SAGE Publishing 2025-03-01
Schriftenreihe:	Therapeutic Advances in Medical Oncology
Online-Zugang:	https://doi.org/10.1177/17588359251328457
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!